NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company	General
Roche (Atezolizumab, bevacizumab)	Allied Health Professionals Federation
	All Wales Therapeutics and Toxicology
Patient/carer groups	Centre
 Addenbrookes Liver Transplant Association 	 Board of Community Health Councils in Wales
 Black Health Agency British Liver Trust 	British National FormularyCare Quality Commission
Cancer Black Care	 Care Quality Commission Department of Health, Social Services
 Cancer Equality 	and Public Safety for Northern Ireland
Cancer 52	 Healthcare Improvement Scotland
Children's Liver Disease Foundation	Medicines and Healthcare products
Chinese National Healthy Living	Regulatory Agency
Centre	National Association of Primary Care
Helen Rollason Cancer Charity	National Pharmacy Association
Hepatitis B Foundation UK	NHS Alliance
Hepatitis C Trust	 NHS Confederation
Independent Cancer Patients' Voice	 Scottish Medicines Consortium
Liver4Life	 Welsh Health Specialised Services
 Macmillan Cancer Support 	Committee
 Maggie's Centres 	
Marie Curie	Possible Comparator companies
Muslim Council of Britain	Bayer (sorafenib)
Pelican Cancer Foundation	 Eisai (lenvatinib)
South Asian Health Foundation	Relevant Research groups
Specialised Healthcare Alliance	Cochrane Hepato-biliary Group
Tenovus Cancer Care	Cochrane Infectious Diseases Group
Professional groups	 Foundation for Liver Research
 Association of Anaesthetists of Great 	Guts UK
Britain & Ireland	Institute of Cancer Research
 Association of Cancer Physicians 	MRC Clinical Trials Unit
Association of Surgeons of Great	National Cancer Research Institute
Britain and Ireland	National Cancer Research Network
• British Association of the Study of the	National Institute for Health Research
Liver	
 British Geriatrics Society 	Associated Public Health Groups

Final stakeholder list for the technology appraisal of atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma ID1655. Issue date: February 2020 © National Institute for Health and Care Excellence 2020. All rights reserved.

Appendix (
Consultees	Commentators (no right to submit or appeal)
 British Institute of Radiologists British Liver Nurses Association British Psychosocial Oncology Society British Society of Gastroenterology Cancer Research UK Hepatitis Nurse Specialist Forum Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal Society of Medicine Society and College of Radiologists UK Clinical Pharmacy Association UK Health Forum UK Oncology Nursing Society 	 Public Health England Public Health Wales
Others Department of Health and Social Care NHS Nene CCG NHS West Suffolk CCG NHS England Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Documentation (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Documentation (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

Final stakeholder list for the technology appraisal of atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma ID1655. Issue date: February 2020 © National Institute for Health and Care Excellence 2020. All rights reserved.